A pilot randomised controlled trial of the efficacy of RRx-001 macrophage-targeted immunotherapy in the management of endometriosis-associated pain Why?We therefore aim to examine the safety/tolerability of RRx-001 immunotherapy in patients with endometriosis. In addition, we will generate data that will inform the design of a future larger definitive trial to determine the efficacy of RRx-001 in the management of endometriosis-associated pain.Who?• Pre-menopausal women and those assigned female at birth• Aged 18 years and over• Chronic pelvic pain of > six months duration from date of consent as per patient reported history• Endometriosis identified at laparoscopy or imaging within the last five years from date of consent• Use of effective barrier contraception for the duration of their participation (if required)*Where?NHS Lothian When?Recruitment is planned to start in the summer of 2025.Recruitment target36 participants More informationFor further details, please contact Priscilla.Fernandez@ed.ac.uk. Please type “MAC-Endo patient enquiry” in the email title section. This will help the team reply to your query sooner. This article was published on 2025-03-05
